Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $15.00 at HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) had its target price hoisted by HC Wainwright from $9.00 to $15.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, JonesTrading assumed coverage on Armata Pharmaceuticals in a report on Monday, January 5th. They issued a “buy” rating and a $15.00 target price for the company. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

Armata Pharmaceuticals Price Performance

Shares of ARMP stock opened at $9.54 on Monday. The firm has a 50-day moving average of $6.92 and a 200-day moving average of $5.22. Armata Pharmaceuticals has a one year low of $0.90 and a one year high of $16.34. The company has a market cap of $347.35 million, a P/E ratio of -5.89 and a beta of 1.42.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Armata Pharmaceuticals by 26.1% during the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after buying an additional 10,500 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Armata Pharmaceuticals by 65.9% in the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after acquiring an additional 27,200 shares in the last quarter. Geode Capital Management LLC lifted its position in Armata Pharmaceuticals by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after acquiring an additional 5,342 shares during the period. Millennium Management LLC bought a new stake in Armata Pharmaceuticals during the fourth quarter worth about $164,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Armata Pharmaceuticals in the fourth quarter worth about $177,000. 3.57% of the stock is owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.